Latest news with #VeronaPharmaplc
Yahoo
a day ago
- Business
- Yahoo
Jefferies Backs Verona Pharma plc (VRNA) After Strong Ohtuvayre Launch
Verona Pharma plc (NASDAQ:VRNA) is among the 10 Best Growth Stocks Under $100 to Buy Now. Analysts at Jefferies have raised the price target for Verona Pharma plc (NASDAQ:VRNA) to $110, up from $95, with an unchanged 'Buy' rating. This was after the successful launch of the COPD treatment Ohtuvayre, which has witnessed strong sales growth. During the first quarter, Ohtuvayre delivered $71 million in sales, reflecting an increase of nearly 90% from the previously reported 37 million in the last quarter. Verona Pharma plc (NASDAQ:VRNA) continues to capitalize on this growing demand, with peak sales projections between $3 billion and $5 billion. As the numbers suggest, this is anything but ordinary. The optimism surrounding the company's profitability in the second quarter is just the cherry on top. A patient in a clinic, taking a medication dose from a nebulizer to treat a respiratory disease. Some believe that Verona Pharma plc (NASDAQ:VRNA) is heading north to be the next big franchise. With its potential, Wall Street anticipates the giant to achieve $1 billion in sales by 2028, driven by its safety profile, global expansion, robust patent protection, and an underserved market of 398 million people with COPD. Verona Pharma plc (NASDAQ:VRNA) is a London-based biopharmaceutical company that develops and markets therapies for treating patients suffering from respiratory diseases. Incorporated in 2005, the company is committed to improving the lives of many by offering innovative drugs. While we acknowledge the potential of VRNA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Yahoo
a day ago
- Business
- Yahoo
Jefferies Backs Verona Pharma plc (VRNA) After Strong Ohtuvayre Launch
Verona Pharma plc (NASDAQ:VRNA) is among the 10 Best Growth Stocks Under $100 to Buy Now. Analysts at Jefferies have raised the price target for Verona Pharma plc (NASDAQ:VRNA) to $110, up from $95, with an unchanged 'Buy' rating. This was after the successful launch of the COPD treatment Ohtuvayre, which has witnessed strong sales growth. During the first quarter, Ohtuvayre delivered $71 million in sales, reflecting an increase of nearly 90% from the previously reported 37 million in the last quarter. Verona Pharma plc (NASDAQ:VRNA) continues to capitalize on this growing demand, with peak sales projections between $3 billion and $5 billion. As the numbers suggest, this is anything but ordinary. The optimism surrounding the company's profitability in the second quarter is just the cherry on top. A patient in a clinic, taking a medication dose from a nebulizer to treat a respiratory disease. Some believe that Verona Pharma plc (NASDAQ:VRNA) is heading north to be the next big franchise. With its potential, Wall Street anticipates the giant to achieve $1 billion in sales by 2028, driven by its safety profile, global expansion, robust patent protection, and an underserved market of 398 million people with COPD. Verona Pharma plc (NASDAQ:VRNA) is a London-based biopharmaceutical company that develops and markets therapies for treating patients suffering from respiratory diseases. Incorporated in 2005, the company is committed to improving the lives of many by offering innovative drugs. While we acknowledge the potential of VRNA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
13-05-2025
- Business
- Yahoo
Why Verona Pharma plc (VRNA) is Among the Best Performing Healthcare Stocks to Buy Now
We recently published a list of . In this article, we are going to take a look at where Verona Pharma plc (NASDAQ:VRNA) stands against other best performing healthcare stocks to buy now. On April 15, CNBC reported that President Trump's healthcare-focused executive order brought in a win for the sector. Trump directed his health department to collaborate with Congress to revamp a law allowing Medicare to negotiate prescription drug prices. The announcement seeks to bring a change that the pharmaceutical company has lobbied for. Since the negotiation process is included in legislation, Trump's executive order cannot implement the change itself. However, it directs Secretary of Health and Human Services Robert F. Kennedy Jr. to join hands with Congress and change it. CNBC reported that drug makers have been working to delay the eligibility timeline for small-molecule drugs to be available for price negotiations by four years. This typically includes pills and most medications. This goes hand in hand with the 13-year wait until more complex biotech drugs are eligible for Medicare price negotiations. Trump's wide-ranging executive order also focuses on slashing healthcare costs. It comes a day after the administration instituted a national security report on the pharma industry. CNBC called the report 'a precursor to sector-specific tariffs.' READ ALSO: Recession Resistant Investing: 10 Best Grocery Stocks To Buy Now and 11 Most Promising Future Stocks According to Hedge Funds. Medicare's negotiating powers have been a subject of contention, as drug makers have opined that they would suppress innovation and have rallied against the time frame for negotiation eligibility for most drugs. The law now allows the government to negotiate prices for drugs with no competition, which includes complex biotech or biologic medications after 13 years on the market, but 9 years for their administration as capsules and pills. Although they did not provide specifics, White House officials told reporters that other changes to the negotiation process would yield more savings than those attained during the first round under the Biden administration. While the Biden administration negotiated price cuts as steep as 79% for the first ten most expensive drugs to the Medicare program, the Trump administration would negotiate prices for the following 15 medications. This includes Pfizer's cancer drugs Ibrance and Xtandi, as well as Novo Nordisk's blockbuster diabetes and weight-loss treatments Ozempic and Wegovy. We used Finviz to screen healthcare stocks and selected the best performers based on their year-to-date (YTD) performance, as of May 9, 2025. We also included the number of hedge fund holders for each stock as of Q4 2024. We sourced the hedge fund sentiment data from Insider Monkey's database. The list is sorted in ascending order of year-to-date performance. Why do we care about what hedge funds do? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (). A patient in a clinic, taking a medication dose from a nebulizer to treat a respiratory disease. YTD Performance: 36.35% Number of Hedge Fund Holders: 42 Verona Pharma plc (NASDAQ:VRNA) is a UK-based biopharmaceutical company that develops and commercializes therapeutics for treating respiratory diseases with unmet medical needs. The FDA's June 2024 approval of its drug Ohtuvayre to treat chronic obstructive pulmonary disease was a significant catalyst for the company. Analysts project this blockbuster drug's sales potential to top $1 billion by 2029. On May 2, Wells Fargo analyst Tiago Fauth raised the firm's price target on Verona Pharma plc (NASDAQ:VRNA) to $107 from $93, keeping an Overweight rating on the shares. The analyst noted that the fiscal Q1 2025 Ohtuvayre sales of $71 million marked the third consecutive quarter of the drug tracking above Trelegy and Breztri, saying that this 'easily justifies ~$3 billion in peak sales, with ~$5 billion+ being a real possibility.' The analyst further said that Verona Pharma plc (NASDAQ:VRNA) added an incremental $31 million and $35 million in fiscal Q4 2024 and fiscal Q1 2025, respectively, reflecting accelerating growth. This shows that there are reasons to believe in the company's continually accelerating growth. Roth Capital also raised the firm's price target on Verona Pharma plc (NASDAQ:VRNA) to $92 from $83 on April 30, keeping a Buy rating on the stock after it reported fiscal Q1 2025 results. Overall, VRNA ranks 10th on our list of the best performing healthcare stocks to buy now. While we acknowledge the potential for VRNA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than VRNA but trades at less than 5 times its earnings, check out our report about this cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
08-05-2025
- Business
- Yahoo
What Makes Verona Pharma plc (VRNA) a Good Investment?
Buckley Capital Advisors, an investment management company, released its first quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund returned -0.5% (net) in the quarter compared to -7.7% return for iShares Russell 2000 Value Index and -9.5% return for the iShares Russell 2000 Index. In the quarter, Donald Trump's aggressive tariff plans increased economic uncertainty. Although tariffs directly impact less than 5% of the portfolio, the firm was prepared for this situation. However, the widespread selling of stocks affected it significantly. The firm focuses on the fundamentally strong companies regardless of the economic environment. In addition, you can check the fund's top 5 holdings to determine its best picks for 2025. In its first-quarter 2025 investor letter, Buckley Capital Advisors highlighted stocks such as Verona Pharma plc (NASDAQ:VRNA). Verona Pharma plc (NASDAQ:VRNA) is a biopharmaceutical company. The one-month return of Verona Pharma plc (NASDAQ:VRNA) was 23.24%, and its shares gained 350.61% of their value over the last 52 weeks. On May 7, 2025, Verona Pharma plc (NASDAQ:VRNA) stock closed at $69.14 per share with a market capitalization of $8.699 billion. Buckley Capital Advisors stated the following regarding Verona Pharma plc (NASDAQ:VRNA) in its Q1 2025 investor letter: "Verona Pharma plc (NASDAQ:VRNA) has developed a product called ensifentrine (Ohtuvayre), a bronchodilator and anti-inflammatory agent for maintenance treatment of COPD. COPD, more commonly known as smoker's lung, is caused by pollution or smoking. Diagnosis of COPD lowers life expectancy by approximately 6 years. Symptoms of COPD are shortness of breath, cough, wheezing, and sputum. COPD affects approximately 400 million people worldwide, with 8.6m people treated in the United States. A patient in a clinic, taking a medication dose from a nebulizer to treat a respiratory disease. Verona Pharma plc (NASDAQ:VRNA) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 42 hedge fund portfolios held Verona Pharma plc (NASDAQ:VRNA) at the end of the fourth quarter, compared to 25 in the third quarter. Verona Pharma plc (NASDAQ:VRNA) reported revenue of $76.3 million in the first quarter, which was in line with prior quarters. While we acknowledge the potential of Verona Pharma plc (NASDAQ:VRNA) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. In another article, we covered Verona Pharma plc (NASDAQ:VRNA) and shared the list of best multibagger stocks to buy according to billionaires. In addition, please check out our hedge fund investor letters Q1 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: Michael Burry Is Selling These Stocks and A New Dawn Is Coming to US Stocks. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
02-05-2025
- Business
- Yahoo
Why Verona Pharma plc (VRNA) Soared on Tuesday
We recently published an article titled . In this article, we are going to take a look at where Verona Pharma plc (NASDAQ:VRNA) stands against the other stocks that soared on Tuesday. The stock market finished Tuesday's trading on a positive note with all major indices ending in the green, buoyed by the influx of corporate earnings results. The Dow Jones grew by 0.75 percent, the S&P 500 rose by 0.58 percent, and the Nasdaq was up by 0.55 percent. Ten companies mirrored the broader market optimism, leading the charge with strong gains, predominantly driven by impressive earnings results. To come up with the list, we considered only the stocks with a $2-billion market capitalization and $5-million trading volume. A patient in a clinic, taking a medication dose from a nebulizer to treat a respiratory disease. Verona Pharma plc (NASDAQ:VRNA) extended its rally for an eighth straight day on Tuesday, adding 6.37 percent to end at $73.21 apiece after the company posted an impressive earnings performance during the first three months of the year. In its earnings release, Verona Pharma plc (NASDAQ:VRNA) said that it narrowed its net loss by 36.8 percent to $16.3 million from $25.79 million in the same period a year earlier. Net revenues stood at $76.3 million, primarily driven by $71.3 million in net sales from Ohtuvayre, the company's maintenance treatment of COPD. In February this year, Verona Pharma plc (NASDAQ:VRNA), through its partner Nuance Pharma, secured the green light of the Macau government to sell Ohtuvayre in the special administrative region. Commenting on its strong performance, VRNA President and CEO David Zaccardelli said: 'We are extremely pleased to report that for the first time, Verona's quarterly revenue exceeded our operating expenses, excluding non-cash charges. We believe we are in a robust financial position to continue commercializing Ohtuvayre, advance our clinical pipeline, and implement our global strategy.' Overall VRNA ranks 6th on our list of the stocks that soared on Tuesday. While we acknowledge the potential of VRNA as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than VRNA but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock. READ NEXT: and . Disclosure: None. This article is originally published at . Sign in to access your portfolio
